TraceBridge AI

MVP Requirements Document

Prepared by James N. Hardison II  |  Date: July 31, 2026  |  Status: Draft v1.0

1. Purpose & Overview

TraceBridge AI is a RAG-based regulatory and quality intelligence platform for early-stage and mid-market medical device companies. It provides regulatory compliance guidance, complaint aggregation and analysis, and customized compliance reporting at a fraction of the cost of enterprise eQMS platforms such as Greenlight Guru or AI-native compliance platforms such as Ketryx.

This document defines the functional and non-functional requirements for the Minimum Viable Product (MVP), targeted for pilot deployment by mid-August 2026, with at least three pilot customers secured by the end of summer 2026.

2. Target Market & Customer Segments

Primary segment: early-stage (pre-commercial to Series A) medical device companies with 5–50 employees across combined Regulatory Affairs and Quality functions.

Secondary segment: growth-stage medtech companies experiencing rapid scaling and complaint/documentation volume they cannot manage manually (e.g., DEKA-scale organizations).

Buyer personas: Regulatory Affairs Manager/Director, Quality Director, Compliance Officer, VP of Engineering at companies priced out of, or underserved by, Greenlight Guru and Ketryx.

3. Competitive Context (Summary)

Full competitive analysis is documented in the TraceBridge AI R&D Log (July 31, 2026). Key takeaways driving requirements:

Greenlight Guru: comprehensive but expensive, dated UI, weak search/navigation, limited external collaboration, weak dashboards — TraceBridge differentiates on price, natural-language search, modern UI, and proactive AI-generated reporting.

Ketryx: AI-native, well-funded ($39M Series B), but requires existing developer toolchain (Jira/GitHub) integration and targets larger, more technically mature teams — TraceBridge differentiates by requiring no developer toolchain and serving budget-constrained early-stage teams directly.

Validated industry pain points (per Greenlight Guru 2025 Industry Report, Veeva 2023 Regulatory Benchmark Report, IQVIA 2025 analysis): complaint/adverse-event handling breaks down at scale, regulatory/quality data lives in silos, and regulatory intelligence monitoring remains a manual, reactive process.

4. MVP Functional Requirements

4.1 Module 1 — RAG Regulatory Guidance Engine (Core / Foundation)

Users can upload device specifications, design documents, and existing submission drafts.

System retrieves and synthesizes relevant FDA guidance, ISO standards, and precedent submission language in response to natural-language questions.

System assists in drafting submission sections (e.g., 510(k) summary components, Design History File sections).

All AI-generated guidance is labeled with a confidence indicator and a disclaimer that a qualified regulatory professional must review and validate outputs prior to submission.

Base model is trained on publicly available FDA guidance, 21 CFR text, and ISO standards; no customer data is used for model training without explicit, separate consent.

4.2 Module 2 — Customized Compliance Reporting

Base (pre-built) reports:

Submission Readiness Report — gap analysis against FDA submission expectations.

Risk Summary Report — severity-ranked compliance weak spots.

Competitive Landscape Report — how comparable devices in-class have addressed specific regulatory requirements.

Timeline Projection Report — estimated submission-readiness timeline based on completed work.

Customization layer:

Users can select data elements, compliance areas, and insight types to build custom reports.

Implementation approach (template selection vs. natural-language report builder vs. drag-and-drop) is open for design exploration and documented separately in the Design Document.

4.3 Module 3 — Complaints & Adverse Event Aggregation (Primary Revenue Driver)

Ingest complaints from multiple channels (email, web forms, support tickets, manual entry; additional connectors post-MVP).

AI-based classification of each complaint by device component, failure type, and severity.

Automated trend detection — flag clusters of related complaints suggesting a potential safety signal.

Auto-generate draft CAPA and MDR (21 CFR Part 803) report templates from classified complaint data.

Maintain full traceability from raw complaint intake through classification, investigation, and closure.

Validated need: DEKA Research & Development (per direct interview discussion) identified complaint aggregation as an acute, unmanaged pain point during periods of rapid company growth — supporting willingness to pay a premium for this module specifically.

4.4 Module 4 — Regulatory Change Impact Analysis

System monitors a regulatory intelligence feed (e.g., RegDesk or IQVIA subscription) for FDA/EU MDR guidance changes relevant to the customer's device classification.

When a relevant change is detected, system automatically flags which sections of the customer's current submissions or SOPs may require updates.

Retraining/refresh cadence: quarterly to semi-annual for MVP; direct FDA scraping and/or API integration reserved for a later phase.

4.5 Internal Tool — Submission Status Tracker

Not a standalone sellable module at MVP, but a required internal-facing capability to support delivery to the BU Spark team and to give customers submission visibility:

Maps FDA submission requirements to the customer's device specifications.

Tracks completion status per section; flags missing documentation.

Displays estimated timeline to submission readiness.

Integrates with Module 1 (guidance per section) and Module 3 (surfaces complaint-driven documentation impacts).

5. Cross-Module Integration Requirements

A complaint classified in Module 3 that meets a materiality threshold triggers a flag in Module 1/4 indicating a possible regulatory or submission impact.

A regulatory change detected in Module 4 triggers a review flag in the Submission Status Tracker for any affected, in-progress submission section.

All modules read/write to a shared data model (see Design Document, Data Dictionary) to avoid duplicate data entry.

6. Non-Functional Requirements

6.1 Data Security & Privacy

SOC 2 compliance roadmap (Type I at minimum before first paid pilot conversion).

Encryption at rest and in transit.

Role-based access control (RBAC) at the module and document level.

Full audit logging of user actions and AI-generated outputs.

Defined data residency (U.S.-based cloud infrastructure) and data retention policy.

Data Processing Agreement (DPA) template defining data ownership, retention, and breach-notification terms for every customer.

Explicit, written confirmation to customers that their proprietary data is never used to train shared/base models without separate opt-in.

6.2 AI Trust & Liability Positioning

Every AI-generated output (guidance, classification, draft report) carries a visible confidence indicator and human-review disclaimer.

TraceBridge is positioned as a regulatory intelligence assistant, not a replacement for a qualified regulatory professional's sign-off.

6.3 Interoperability

API or structured import/export to reduce friction for customers already using Greenlight Guru or another eQMS, positioning TraceBridge as complementary rather than a forced replacement.

6.4 Performance & Reliability

Target: sub-5-second response time for RAG guidance queries under normal load.

Target: complaint classification throughput sufficient to handle 500+ complaints/month per customer (DEKA-scale validation benchmark).

7. Data Requirements & Sourcing

Complaints/adverse event training data: FDA MAUDE database (public).

V&V and regulatory guidance training data: publicly available FDA guidance documents, ISO standards, publicly filed FDA submission dockets.

CAPA/complaint workflow templates: published regulatory consulting guidance, medical device association resources (e.g., AdvaMedDx), and internal domain expertise (Abbott, Insulet, J&J MedTech).

Pilot customer data: anonymized historical complaint data contributed voluntarily in exchange for discounted early pricing; used only with explicit consent.

A full Data Dictionary (complaint schema, regulatory requirement taxonomy, quality workflow fields, supplier data structure) is required as a BU Spark deliverable and is addressed in the Design Document.

8. Testing & Validation Requirements

Unit testing per module (RAG relevance/coherence, complaint classification accuracy, report rendering correctness) using automated test suites and mock data, ongoing during development.

Integration testing of cross-module data flows (complaint → regulatory flag; regulatory change → submission tracker flag).

Pilot validation testing with live pilot customers using real (anonymized, consented) complaint and regulatory data in parallel with development.

Accuracy validation: manual sampling of AI-generated complaint classifications against ground truth; regulatory-expert review of RAG guidance outputs; ongoing false-positive/false-negative tracking.

All testing methodology and results documented to support future audit trail and customer trust conversations.

9. Explicitly Out of Scope for MVP

Autonomous AI agents (e.g., unsupervised monitoring/investigation agents) — reserved for Q4 2026/Q1 2027 once sufficient customer usage data exists.

Post-market surveillance automation (full field-performance correlation) — reserved for a later phase; mandatory but too large in scope for summer MVP.

Design change impact analysis and supplier compliance verification (originally scoped Quality Control module components) — reserved for post-MVP phase.

Direct FDA website scraping / FDA API integration — reserved; MVP relies on a third-party regulatory intelligence subscription (RegDesk/IQVIA) instead.

Clinical data integration/harmonization — backlog.

10. Milestones

Milestone

Target Date

Notes

BU Spark project deliverables (data dictionary, initial functional demo)

End of July 2026

Existing BU Spark deadline

Operational MVP (Modules 1–4 + internal Submission Tracker)

Mid-August 2026

Functional, pilot-ready build

Pilot customer outreach materials (one-pager / pitch deck)

Mid-August 2026

Built from this requirements set

Minimum 3 signed pilot customers

End of Summer 2026

Complaints module positioned as lead offer

11. Pricing Guidance (Reference)

Complaints module (primary revenue driver): $1,500–$2,000/month for early-stage companies; $3,000–$5,000/month for higher-volume, growth-stage companies (e.g., DEKA-scale).

RAG guidance and customized reporting bundled with complaints module in MVP pricing; not sold standalone at this stage.

Regulatory Change Impact Analysis positioned as a near-term add-on/upsell once core modules are validated with pilots.

